Rob Finizio, TherapeuticsMD co-founder and CEO, discusses the company's focus on women's health and development of advanced hormone replacement therapies.» Read More
A study by a few accounting professors at the University of Michigan shows that analyst reports for companies whose 10-Ks are hard to read might be more informative, but they're associated with “greater dispersion, lower accuracy, and greater overall uncertainty in earnings forecasts.”
The Federal Reserve's zero-interest-rate policies are making it impossible for investors to make money by holding Treasurys, Pimco's Bill Gross told CNBC.
To see two analysts downgrade shares Gap today makes you wonder what they know and investors don’t. Or, based on the performance of Gap’s stock, what investors knew and the analysts didn’t — until now?
Biotechs are addicted to capital like "crack addicts are addicted to crack," because of the $1 billion-plus price tag that it takes to bring a drug to market, Gregory Brown, founder and managing director of Cowen Healthcare Royalty Partners, told CNBC Monday.
William Gross, PIMCO co-CIO & founder, with perspective on S&P's negative outlook on U.S. credit and what the downgrade means for the markets.
"The whole thing makes no sense to me," says one CIO. "I can't tell a consistent story that explains all of these facts. My working hypothesis is this whole thing is ephemeral—people were looking for a reason to sell stocks today."
The market’s so-called fear indicator is not always a good predictor of where the market is headed. But futures on the CBOE Volatility Index can often say a lot about where the VIX itself is headed, says Randy Frederick, director of trading and derivatives at Charles Schwab.
Although Citigroup posted a quarterly profit narrowly beating Wall Street forecasts Monday, Anthony Polini, equity analyst at Raymond James, is bullish on the stock.
The inflation picture in the U.S. is mixed, but elsewhere in the world prices are rising steadily. Here's how to respond.
Amelia Bourdeau,, Westpac Institutional Bank with her perspective on the U.S. dollar vs other currencies.
A look at how to profit and protect your investments after S&P's negative credit outlook, with the Fast Money traders and Christopher Whalen, Institutional Risk Analytics.
Greg Brown, founder at private equity firm Cowen Healthcare Royalty Partners, discusses which health care assets offer value to investors now. Plus, he reveals what biotech name could be the next takeover target.
Greg Brown, Cowen Healthcare Royalty Partners with his picks for the best plays on healthcare takeover targets.
Standard & Poor's downgrade of its outlook on the US to negative will have no effect on investing strategy, Rubino Financial President Michael Rubino told CNBC Monday.
Stocks continued to tumble on news Standard & Poor's has a negative outlook on the U.S.'s long-term debt, citing concerns lawmakers will be unable to come to an agreement to address budgetary challenges.
The Health Care SPDR exchange-traded fund has been rising with some healthy option paper and on Friday closed at its highest price since early 2008. Multiple names in the sector have been targeted as well.
"Although we believe these strengths currently outweigh what we consider to be the U.S.'s meaningful economic and fiscal risks and large external debtor position, we now believe that they might not fully offset the credit risks over the next two years at the 'AAA' level," said Standard & Poor's credit analyst Nikola G. Swann.
Here's why you should keep a close eye on these six stocks.
Insight on the rise in gold, oil and cotton prices, with Alan Knuckman, Agora Financial; Addison Armstrong, Tradition Energy, and David Morgan, The Morgan Report.
It's a holiday-shortened week, with many traders already off for Passover or Easter. While it's unlikely we will see much of the way in heroic trading or heavy volume, we are starting on a weak note.